Calif. biosimilars bill raises costly barriers to drug access

California Gov. Jerry Brown should veto SB 598, which protects the makers of brand-name biologic drugs at the expense of patients and taxpayers, writes Ralph Neas, president and CEO of the Generic Pharmaceutical Association. Broad access to biosimilar drugs could save the state's health care system more than $27.6 billion over a decade, according to an Express Scripts study, but SB 598 would restrict access, Neas writes.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief: